Lorlatinib/lorlatinib targeted drug enters medical insurance price

Lorlatinib (Lorlatinib) is mainly used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body. Larlatinib belongs to the kinase inhibitor class of drugs. It stops cancer cells from multiplying by blocking the action of abnormal proteins, which helps stop or slow the spread of cancer cells. Lorlatinib has been launched in China and has been included in the reimbursement list of Class B medical insurance. Patients who meet the indications can use medical insurance for reimbursement.

Lorlatinib is available as an oral tablet. Usually once daily, it can be taken with or without food. Patients need to take lorlatinib at about the same time every day. Do not take too much or too little or more often than prescribed by the doctor. If you vomit after taking this medication, do not take any more medication and continue with your regular dosing schedule. Patients may swallow the tablets whole; do not cut, chew, or crush them. Do not take tablets that are broken or cracked. Depending on whether the patient experiences any side effects, doctors may reduce the dose of lorlatinib or stop treatment temporarily or permanently.

Lorlatinib is a third-generation anaplastic lymphoma kinase inhibitor (ALK). It has anti-tumor activity especially for patients who have previously received ALK-positive NSCLC treatment, providing patients with an effective treatment option. This drug is marketed in China as lorlatinib tablets. The common specifications are 25mg*90 tablets and 100mg*30 tablets. The price of each box may be about 10,000 yuan. Due to different reimbursement ratios in different regions, the price after reimbursement may be slightly different. For specific relevant information, please consult the local medical insurance bureau or hospital.